Claims for Patent: 6,451,991
✉ Email this page to a colleague
Summary for Patent: 6,451,991
| Title: | Sugar-modified gapped oligonucleotides |
| Abstract: | Oligonucleotides are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary nucleic acid strand, and subsequences of 2'-deoxy-erythro-pentofuranosyl nucleosides that activate RNase H. Such oligonucleotides are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to ooligonucleotide therapeutics. |
| Inventor(s): | Pierre Martin, Karl-Heinz Altmann, Phillip Dan Cook, Brett P. Monia |
| Assignee: | Novartis AG, Ionis Pharmaceuticals Inc |
| Application Number: | US08/802,331 |
| Patent Claims: |
1. An oligonucleotide specifically hybridizable with DNA or RNA said oligonucleotide comprising a linear sequence of covalently-bound nucleoside units, wherein: said sequence comprises a first nucleoside subsequence having adjacent 2′-O—CH2—CH2—O—CH3 sugar moieties and a second nucleoside subsequence having adjacent 2′-deoxy sugar moieties, wherein: said nucleoside units of said first and second subsequences are covalently-bound by phosphorothioate linkages; or said nucleoside units of said first subsequence are covalently-bound by phosphodiester linkages and said nucleoside units of said second subsequence are covalently-bound by phophorothioate linkages; or said nucleoside units of said first subsequence are covalently-bound by phosphorothioate linkages and said nucleoside units of said second subsequence are covalently-bound by phosphodiester linkages. 2. The oligonucleotide of claim 1 wherein said nucleoside units of said first and second subsequences are covalently-bound by phosphorothioate linkages. 3. The oligonucleotide of claim 1 wherein said nucleoside units of said first subsequence are covalently-bound by phosphodiester linkages and said nucleoside units of said second subsequence are covalently-bound by phosphorothioate linkages. 4. The oligonucleotide of claim 1 wherein said nucleoside units of said first subsequence are covalently-bound by phosphorothioate linkages and said nucleoside units of said second subsequence are covalently-bound by phosphodiester linkages. 5. The oligonucleotide of claim 1 wherein said second subsequence comprises at least three nucleoside units. 6. The oligonucleotide of claim 1 wherein said second subsequence comprises at least five nucleoside units. 7. The oligonucleotide of claim 1 having 5 to 50 nucleoside units. 8. An oligonucleotide specifically hybridizable with DNA or RNA said oligonucleotide comprising a linear sequence of covalently-bound nucleoside units, wherein: said sequence comprises a first nucleoside subsequence having adjacent 2′-OCH2—CH2—O—CH3 sugar moieties, a second nucleoside subsequence having adjacent 2′-deoxy sugar moieties, and a third nucleoside subsequence having adjacent 2′-O—CH2—CH2—O—CH3 sugar moieties, wherein said second subsequence is positioned between said first and third subsequences; and the nucleoside units within said first, second, and third subsequences are covalently-bound by phosphodiester or phophorothioate linkages. 9. The oligonucleotide of claim 8 wherein said nucleoside units of said first, second and third subsequences are covalently-bound by phosphorothioate linkages. 10. The oligonucleotide of claim 8 wherein said nucleoside units of said first and thir subsequences are covalently-bound by phosphodiester linkages and said nucleoside units of said second subsequence are covalently-bound by phosphorothioate linkages. 11. The oligonucleotide of claim 8 wherein said nucleoside units of said first and third subsequences are covalently-bound by phosphorothioate linkages and said nucleoside units of said second subsequence are covalently-bound by phosphodiester linkages. 12. The oligonucleotide of claim 8 wherein said second subsequence comprises at least three nucleoside units. 13. The oligonucleotide of claim 8 wherein said second subsequence comprises at least five nucleoside units. 14. The oligonucleotide of claim 8 having 5 to 50 nucleoside units. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
